01
Materials and Methods
Blood Sample Collection
Blood was collected from healthy volunteers with normal coagulation function using BD blue-top blood collection tubes. These samples served as the experimental material for subsequent drug treatment and testing, excluding interference from pre-existing coagulation abnormalities in the volunteers.
Tirofiban Treatment
Tirofiban dissolved in a citrate-based buffer was added to the collected blood to prepare two groups of samples at final concentrations of 0.5 μg/mL and 1.0 μg/mL. The purpose was to inhibit platelet function and observe how platelet inhibition affected anticoagulation across the overall process of thrombus formation in whole blood.
Platelet Function Testing
Platelet function was assessed using the platelet mapping mode of the ATEG analyzer. Arachidonic acid (AA) and adenosine diphosphate (ADP) were added separately as platelet activators. After adequate incubation, the samples containing the different tirofiban concentrations were tested, and the corresponding platelet inhibition rates were calculated to verify the inhibitory effect of tirofiban on platelet function.
Quantitative LMWH Testing
The ATEG analyzer was first calibrated against the international LMWH standard, NIBSC 11/176. Its LMWH testing mode quantitatively converts the sample’s anticoagulation level into an LMWH concentration expressed in IU/mL. This mode was then used to test the tirofiban-treated blood samples and obtain their LMWH-equivalent concentrations.
Criteria for Determining Equivalence
Using the analyzer’s preset LMWH calibration curve, the anticoagulant effect in each tirofiban-treated sample was converted into a corresponding LMWH-equivalent concentration. This established the relationship between tirofiban and LMWH effects in the assay and enabled quantitative comparison of anticoagulant effects across drugs with different mechanisms of action.
02
Experimental Results
Verification of Platelet Inhibition
In both groups of blood samples, containing final tirofiban concentrations of 0.5 μg/mL and 1.0 μg/mL, platelet mapping showed inhibition rates exceeding 80% in both the AA and ADP channels. These results indicated marked suppression of platelet responses to the two classical activation pathways. Platelets showed no effective response to activation through either pathway, demonstrating that their prothrombotic function had been blocked and that the prespecified platelet inhibition requirement had been met.
0.5–1.0 μg/mL Tirofiban in vitro
The two tested concentrations were 0.5 and 1.0 μg/mL, with platelet inhibition exceeding 80% in both AA and ADP channels.
0.1–0.2 IU/mL LMWH-equivalent effect
The reported range of equivalent anticoagulant activity was determined using the calibrated quantitative LMWH testing mode.
LMWH-Equivalent Anticoagulation Levels
The platelet-inhibited samples were tested using the analyzer’s calibrated quantitative LMWH mode. The anticoagulant effects produced by the two tirofiban concentrations were comparable to those produced by LMWH at 0.1–0.2 IU/mL, yielding a quantitative conversion of the tirofiban effect into an LMWH-equivalent anticoagulation level.
03
Discussion
Applicability Across Different Drug Mechanisms
The study found that quantitative LMWH testing with the thromboelastography analyzer could characterize the overall antithrombotic effect of tirofiban, whose primary action is platelet inhibition. The assay did not require a distinction between inhibition of platelet aggregation and inhibition of coagulation factor activity. The findings therefore extend the proposed applications of this testing mode to drug effects arising through different mechanisms.
Why Use an LMWH Reference Standard
There are three reasons for using LMWH as the reference for equivalent anticoagulation levels. First, a quantitative method requires a complete traceability chain to an international standard, in this case NIBSC 11/176. Second, the widespread clinical use of LMWH makes it a practical reference for assessing anticoagulation levels. Third, LMWH is chemically stable and easy to store.
Potential Clinical Applications
At the level of overall coagulation function, the study expresses the antiplatelet effect of tirofiban as a quantifiable LMWH-equivalent anticoagulant effect. The authors present this finding as experimental support for assessing treatment intensity and comparing the effects of antithrombotic drugs with different mechanisms, under the assay conditions used in the study.
Illustrative Application in Combination Therapy
The article gives the following proposed example: when an antiplatelet drug is combined with an anticoagulant such as LMWH, and the intended total anticoagulant effect is equivalent to 0.4 IU/mL LMWH, the equivalent effect after antiplatelet treatment could first be measured. LMWH could then be added to bring the total effect to the intended level. The proposed purpose is to achieve the target treatment intensity while avoiding excessive anticoagulation.
Illustrative Application in Drug Bridging
The article also proposes first measuring the equivalent anticoagulation level of a patient’s current drug, using standard LMWH as the reference, when bridging to another anticoagulant is needed. A gradual transition to the intended drug could then be planned on the basis of these equivalent effects, supporting individualized treatment design.
04
Overall Conclusions
Principal Finding
In blood samples with normal coagulation function studied in vitro, tirofiban at 0.5–1.0 μg/mL produced an anticoagulant effect comparable to that of LMWH at 0.1–0.2 IU/mL. The study demonstrates that, within this assay, tirofiban’s antiplatelet effect can be expressed at the level of overall anticoagulation as a quantitative, calibratable LMWH-equivalent effect.
Contribution to Antithrombotic Drug Assessment
The study supports the use of thromboelastography for quantitative assessment of antithrombotic drugs across different mechanisms of action. It also provides a new reference approach for comparing drug effects and monitoring treatment intensity, with the aim of improving the precision and safety of antithrombotic treatment.
中文